Literature DB >> 27596834

Angiotensin II, hypertension and angiotensin II receptor antagonism: Roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease.

Maximilian Wiesmann1,2, Monica Roelofs1, Robert van der Lugt1, Arend Heerschap3, Amanda J Kiliaan1, Jurgen Ahr Claassen2.   

Abstract

Elevated angiotensin II causes hypertension and contributes to Alzheimer's disease by affecting cerebral blood flow. Angiotensin II receptor blockers may provide candidates to reduce (vascular) risk factors for Alzheimer's disease. We studied effects of two months of angiotensin II-induced hypertension on systolic blood pressure, and treatment with the angiotensin II receptor blockers, eprosartan mesylate, after one month of induced hypertension in wild-type C57bl/6j and AβPPswe/PS1ΔE9 (AβPP/PS1/Alzheimer's disease) mice. AβPP/PS1 showed higher systolic blood pressure than wild-type. Subsequent eprosartan mesylate treatment restored this elevated systolic blood pressure in all mice. Functional connectivity was decreased in angiotensin II-infused Alzheimer's disease and wild-type mice, and only 12 months of Alzheimer's disease mice showed impaired cerebral blood flow. Only angiotensin II-infused Alzheimer's disease mice exhibited decreased spatial learning in the Morris water maze. Altogether, angiotensin II-induced hypertension not only exacerbated Alzheimer's disease-like pathological changes such as impairment of cerebral blood flow, functional connectivity, and cognition only in Alzheimer's disease model mice, but it also induced decreased functional connectivity in wild-type mice. However, we could not detect hypertension-induced overexpression of Aβ nor increased neuroinflammation. Our findings suggest a link between midlife hypertension, decreased cerebral hemodynamics and connectivity in an Alzheimer's disease mouse model. Eprosartan mesylate treatment restored and beneficially affected cerebral blood flow and connectivity. This model could be used to investigate prevention/treatment strategies in early Alzheimer's disease.

Entities:  

Keywords:  Alzheimer’s; brain imaging; cerebral blood flow; cognitive impairment; hypertension

Mesh:

Substances:

Year:  2016        PMID: 27596834      PMCID: PMC5531339          DOI: 10.1177/0271678X16667364

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  113 in total

1.  Midlife blood pressure and dementia: the Honolulu-Asia aging study.

Authors:  L J Launer; G W Ross; H Petrovitch; K Masaki; D Foley; L R White; R J Havlik
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

2.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.

Authors:  J L Jankowsky; H H Slunt; T Ratovitski; N A Jenkins; N G Copeland; D R Borchelt
Journal:  Biomol Eng       Date:  2001-06

3.  Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping.

Authors:  S G Kim
Journal:  Magn Reson Med       Date:  1995-09       Impact factor: 4.668

Review 4.  Angiotensin and neurovascular coupling: beyond hypertension.

Authors:  Sherri Bloch; Dima Obari; Hélène Girouard
Journal:  Microcirculation       Date:  2015-04       Impact factor: 2.628

5.  MR perfusion studies with T1-weighted echo planar imaging.

Authors:  K K Kwong; D A Chesler; R M Weisskoff; K M Donahue; T L Davis; L Ostergaard; T A Campbell; B R Rosen
Journal:  Magn Reson Med       Date:  1995-12       Impact factor: 4.668

6.  Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.

Authors:  Elina Zotova; James Ar Nicoll; Raj Kalaria; Clive Holmes; Delphine Boche
Journal:  Alzheimers Res Ther       Date:  2010-01-22       Impact factor: 6.982

7.  Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease.

Authors:  I A Simpson; K R Chundu; T Davies-Hill; W G Honer; P Davies
Journal:  Ann Neurol       Date:  1994-05       Impact factor: 10.422

8.  Reduced hippocampal functional connectivity in Alzheimer disease.

Authors:  Greg Allen; Holly Barnard; Roderick McColl; Andrea L Hester; Julie A Fields; Myron F Weiner; Wendy K Ringe; Anne M Lipton; Matthew Brooker; Elizabeth McDonald; Craig D Rubin; C Munro Cullum
Journal:  Arch Neurol       Date:  2007-10

9.  A mouse model of angiotensin II slow pressor response: role of oxidative stress.

Authors:  Noritaka Kawada; Enyu Imai; Alexsander Karber; William J Welch; Christopher S Wilcox
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

10.  Disrupted Frontoparietal Network Mediates White Matter Structure Dysfunction Associated with Cognitive Decline in Hypertension Patients.

Authors:  Xin Li; Ying Liang; Yaojing Chen; Junying Zhang; Dongfeng Wei; Kewei Chen; Ni Shu; Eric M Reiman; Zhanjun Zhang
Journal:  J Neurosci       Date:  2015-07-08       Impact factor: 6.167

View more
  16 in total

Review 1.  Alzheimer's Disease: The Link Between Amyloid-β and Neurovascular Dysfunction.

Authors:  Ernesto Solis; Kevin N Hascup; Erin R Hascup
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

2.  Two-kidney one-clip is a pertinent approach to integrate arterial hypertension in animal models of stroke: Serial magnetic resonance imaging studies of brain lesions before and during cerebral ischemia.

Authors:  Benjamin Ménard; Laurent Chazalviel; Simon Roussel; Myriam Bernaudin; Omar Touzani
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-15       Impact factor: 6.200

Review 3.  Effects of angiotensin-II on brain endothelial cell permeability via PPARalpha regulation of para- and trans-cellular pathways.

Authors:  Shuzhen Guo; Angel T Som; Ken Arai; Eng H Lo
Journal:  Brain Res       Date:  2019-07-26       Impact factor: 3.252

Review 4.  Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease.

Authors:  Kassandra Kisler; Amy R Nelson; Axel Montagne; Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

5.  Genetic heterogeneity of Alzheimer's disease in subjects with and without hypertension.

Authors:  Alireza Nazarian; Konstantin G Arbeev; Arseniy P Yashkin; Alexander M Kulminski
Journal:  Geroscience       Date:  2019-05-05       Impact factor: 7.713

6.  Hypertension impairs neurovascular coupling and promotes microvascular injury: role in exacerbation of Alzheimer's disease.

Authors:  Anna Csiszar; Stefano Tarantini; Gábor A Fülöp; Tamas Kiss; M Noa Valcarcel-Ares; Veronica Galvan; Zoltan Ungvari; Andriy Yabluchanskiy
Journal:  Geroscience       Date:  2017-08-29       Impact factor: 7.713

7.  Enhanced interstitial fluid drainage in the hippocampus of spontaneously hypertensive rats.

Authors:  Beatrice Bedussi; Daphne M P Naessens; Judith de Vos; Rik Olde Engberink; Micha M M Wilhelmus; Edo Richard; Malyssa Ten Hove; Ed vanBavel; Erik N T P Bakker
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

8.  Do Patient Concerns About Antihypertensive Use For Dementia Prevention Vary By Current Use Of Antihypertensive?

Authors:  Woojung Lee; Shelly L Gray; Douglas Barthold; Paul K Crane; Eric B Larson; Zachary A Marcum
Journal:  Patient Prefer Adherence       Date:  2019-10-23       Impact factor: 2.711

9.  Increases in hypertension-induced cerebral microhemorrhages exacerbate gait dysfunction in a mouse model of Alzheimer's disease.

Authors:  Ádám Nyúl-Tóth; Stefano Tarantini; Tamas Kiss; Peter Toth; Veronica Galvan; Amber Tarantini; Andriy Yabluchanskiy; Anna Csiszar; Zoltan Ungvari
Journal:  Geroscience       Date:  2020-08-25       Impact factor: 7.713

10.  A Network-Based Approach to Explore the Mechanisms of Uncaria Alkaloids in Treating Hypertension and Alleviating Alzheimer's Disease.

Authors:  Wenyong Wu; Zijia Zhang; Feifei Li; Yanping Deng; Min Lei; Huali Long; Jinjun Hou; Wanying Wu
Journal:  Int J Mol Sci       Date:  2020-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.